Trial participants receiving the highest dose of CK-2017357 showed symptom improvement in the first stage of an ongoing phase 2 trial of this experimental drug

Posted on Tuesday, December 13, 2011 - 12:15, By: Amy Madsen
In the first stage of an ongoing phase 2 clinical trial to test the experimental therapy CK-2017357 in amyotrophic lateral sclerosis (ALS), the drug was found to be safe and well-tolerated. Participants who received the highest dose showed improved scores on tests that measure motor and breathing...
Posted on Thursday, September 1, 2011 - 10:35, By: ALSN Staff
Disease 'in a dish' is a new tool for studying ALS An MDA-supported research team has created a human cellular model of ALS using cells taken from people with the ALS8 subtype of the disease, a familial (inherited) form of ALS (amyotrophic lateral sclerosis) caused by mutations in the VAPB gene.

Biotechnology company Cytokinetics has opened enrollment for a phase 2 clinical trial to study its experimental treatment CK-2017357 in ALS

Posted on Friday, July 1, 2011 - 14:34, By: Amy Madsen
San Francisco biotechnology company Cytokinetics announced June 21, 2011, that it has opened enrollment for a new clinical trial of CK-2017357 at three different dosage levels in people with ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease).
Posted on Wednesday, September 1, 2010 - 15:46, By: ALSN Staff
ALS participants sought for study probing oxidative stress Investigators conducting a large study of a cell-damaging phenomenon called “oxidative stress,” common in ALS and other degenerative diseases, are seeking 420 people in whom ALS has recently been diagnosed.
Posted on Saturday, May 1, 2010 - 11:54, By: ALSN Staff
Cytokinetics seeks participants for CK-2017357 study Cytokinetics, a South San Francisco biotechnology company, is seeking participants with ALS for a trial of its experimental compound CK-2017357.